Thailand’s National Center for Genetic Engineering and Biotechnology is expecting two COVID-19 anti-viral nasal sprays to enter human trials by the end of this year. Deputy government spokeswoman Ratchada Thanadirek said on Wednesday the nasal sprays are based on adenovirus and influenza and testing on mice has provided promising results. The first phase of human trials is due to start later this year after pending approval is accepted by the country’s food and drug regulator. Thanadirek noted that the trials will also include the spray’s effectiveness against the Delta variant, with the second phase due in March 2022 and a target of production for wider use in mid-2022, if the results are good. Research has been carried out in countries around the world to develop nasal sprays to help prevent and treat the CCP virus, particularly given that the lining of the nose has been identified as a key entry point …